CACIPLIQ20 in Wound Healing in Subjects With Epidermolysis Bullosa

NCT06007235 · clinicaltrials.gov ↗

NA

Phase

UNKNOWN

Status

16

Enrollment

INDUSTRY

Sponsor class

Conditions

Epidermolysis Bullosa Dystrophica
Epidermolysis Bullosa, Junctional

Interventions

DEVICE: CACIPLIQ20
DRUG: Placebo

Sponsor

Organ, Tissue, Regeneration, Repair and Replacement

Collaborators

[object Object]
[object Object]